Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥3,670 JPY
Change Today 0.00 / 0.00%
Volume 1.1M
As of 2:00 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

nichi-iko pharmaceutical co (4541) Snapshot

Open
¥3,750
Previous Close
¥3,670
Day High
¥3,760
Day Low
¥3,600
52 Week High
08/5/15 - ¥4,720
52 Week Low
09/1/14 - ¥1,606
Market Cap
222.6B
Average Volume 10 Days
1.2M
EPS TTM
¥116.64
Shares Outstanding
60.7M
EX-Date
09/28/15
P/E TM
31.5x
Dividend
¥26.60
Dividend Yield
0.72%
Current Stock Chart for NICHI-IKO PHARMACEUTICAL CO (4541)

Related News

No related news articles were found.

nichi-iko pharmaceutical co (4541) Related Businessweek News

No Related Businessweek News Found

nichi-iko pharmaceutical co (4541) Details

Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, distributes, exports, imports, and related activities for various types of pharmaceuticals. The company primarily focuses on the production of generic drugs. It also offers treatments for circulatory, digestive, respiratory, central and peripheral nervous system disorders, and others. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was founded in 1965 and is headquartered in Toyama, Japan.

1,138 Employees
Last Reported Date: 06/19/15
Founded in 1965

nichi-iko pharmaceutical co (4541) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nichi-iko pharmaceutical co (4541) Key Developments

Nichi-Iko Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2015; Provides Dividend Guidance for the Full Year of Fiscal 2016; Provides Earnings Guidance for the First Half and Full Year of 2016

Nichi-Iko Pharmaceutical Co., Ltd. announced consolidated earnings results for the first quarter ended June 30, 2015. For the period, the company reported net sales of JPY 35,049 million compared with JPY 30,400 million for the same period a year ago. Operating income was JPY 3,169 million compared with JPY 2,593 million for the same period a year ago. Ordinary income was JPY 3,234 million compared with JPY 2,549 million for the same period a year ago. Net income attributable to shareholders of the company was JPY 2,295 million or JPY 38.32 per diluted share compared with JPY 1,913 million or JPY 31.99 per diluted share for the same period a year ago. Net income before provision for income tax was JPY 3,232 million compared with JPY 2,818 million for the same period a year ago. The company provided dividend guidance for the full year of fiscal 2016. The company plans to pay an interim dividend of JPY 13.30 per share and a final dividend of JPY 13.30 per share for the full year of fiscal 2016. The company provided earnings guidance for the first half and full year of 2016. For the first half, the company expects to report net sales of JPY 65,300 million, operating income of JPY 5,200 million, ordinary income of JPY 5,000 million and net income attributable to shareholders of the company of JPY 3,300 million or JPY 55.19 per share. For the full year, the company expects to report net sales of JPY 137,200 million, operating income of JPY 12,500 million, ordinary income of JPY 12,100 million and net income attributable to shareholders of the company of JPY 8,000 million or JPY 133.79 per share.

Nichi-Iko Pharmaceutical Co., Ltd. to Report Q1, 2016 Results on Aug 10, 2015

Nichi-Iko Pharmaceutical Co., Ltd. announced that they will report Q1, 2016 results at 3:00 PM, Tokyo Standard Time on Aug 10, 2015

Nichi-Iko Pharmaceutical Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2015; Provides Earnings Guidance for the First Half and Full Fiscal Year Ending March 31, 2016; Announces Year-End Dividend for the Year Ended March 31, 2015, Payable on June 22, 2015; Provides Second Quarter and Year-End Dividend Guidance for the Year Ending March 31, 201

Nichi-Iko Pharmaceutical Co., Ltd. reported consolidated and non-consolidated earnings results for the year ended March 31, 2015. For the period on consolidated basis, net sales were JPY 127,021 million against JPY 103,622 million a year ago. Operating income was JPY 9,619 million against JPY 7,383 million a year ago. Ordinary income was JPY 9,615 million against JPY 7,085 million a year ago. Net income was JPY 6,592 million or JPY 110.14 per diluted share against JPY 4,588 million or JPY 104.67 per diluted share a year ago. Return on equity was 9.4% against 8.0% a year ago. Cash flow from operating activities was JPY 21,179 million against JPY 5,546 million a year ago. For the period on non-consolidated basis, net sales were JPY 119,994 million against JPY 102,908 million a year ago. Operating income was JPY 8,353 million against JPY 7,435 million a year ago. Ordinary income was JPY 8,626 million against JPY 7,480 million a year ago. Net income was JPY 5,837 million or JPY 97.52 per diluted share against JPY 4,997 million or JPY 113.96 per diluted share a year ago. For the first half of fiscal 2016, the company expects net sales of JPY 65,300 million, operating income of JPY 5,200 million, ordinary income of JPY 5,000 million, and net income attributable to the owners of the parent of JPY 3,300 million or JPY 55.18 per share. For the full year of fiscal 2016, the company expects net sales of JPY 137,200 million, operating income of JPY 12,500 million, ordinary income of JPY 12,100 million, and net income attributable to the owners of the company of JPY 8,000 million or JPY 133.78 per share. The company announced year-end dividend of JPY 14.30 per share for the year ended March 31, 2015, payable on June 22, 2015. The company expects second quarter dividend of JPY 13.30 per share for the year ending March 31, 2016. The company expects year-end dividend of JPY 13.30 per share for the year ending March 31, 2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4541:JP ¥3,670.00 JPY 0.00

4541 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4541.
View Industry Companies
 

Industry Analysis

4541

Industry Average

Valuation 4541 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NICHI-IKO PHARMACEUTICAL CO, please visit www.nichiiko.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.